How to Select Pharma Packaging for Blood Products

Blood products — including human serum albumin, immunoglobulins, coagulation factors, and other plasma-derived biologics — represent one of the fastest-growing segments of the Chinese injectable drug market, with compound annual growth of 18% since 2018 and more than 30 operating manufacturers. Their sensitivity to oxidation, protein aggregation, and packaging material interaction places exacting demands on elastomeric container closure components across the full vial, cartridge, and prefilled syringe formats in which these products are distributed. This on-demand webinar, presented by Datwyler's China Technical Key Account Manager, provides pharmaceutical packaging professionals with a structured component selection framework aligned to the drug development lifecycle — from preclinical through commercial scale-up — covering compound recommendation and extractables and leachables (E/L) documentation requirements under ChP (Chinese Pharmacopoeia) and international standards, functional evaluation criteria for vial stoppers and seals including container closure integrity and machinability, and Datwyler's complete product portfolio for blood product applications: vial stoppers and aluminum seals, cartridge combiseals and plungers, and prefilled syringe components available in bulk, RFS, RTU, and Rapid Transfer Port (RTP) bag formats. The session also addresses China-specific regulatory considerations and the packaging distribution landscape for injectables in the Chinese market.